Zenlabs Ethica (BOM:530697) Cyclically Adjusted Revenue per Share: ₹123.36 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:530697 Zenlabs Ethica Ltd BOM:530697
61 GF Score
Price ₹26.00
GF Value ₹28.90
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Zenlabs Ethica Cyclically Adjusted Revenue per Share?

Zenlabs Ethica BOM:530697 +0.78% 61 Cyclically Adjusted Revenue per Share is ₹123.36 as of Mar. 2026. GuruFocus rates BOM:530697 with a GF Score™ of 61/100 and a GF Value™ of ₹28.90 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Zenlabs Ethica's adjusted revenue per share for the three months ended in Mar. 2026 was ₹16.258. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹123.36 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Zenlabs Ethica's average Cyclically Adjusted Revenue Growth Rate was -0.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -0.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 2.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Zenlabs Ethica was 7.00% per year. The lowest was -0.60% per year. And the median was 0.70% per year.

As of today (2026-08-21), Zenlabs Ethica's current stock price is ₹26.00. Zenlabs Ethica's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ₹123.36. Zenlabs Ethica's Cyclically Adjusted PS Ratio of today is 0.21.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zenlabs Ethica was 0.62. The lowest was 0.14. And the median was 0.31.


Zenlabs Ethica  (BOM:530697) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Zenlabs Ethica's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=26.00/123.36
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zenlabs Ethica was 0.62. The lowest was 0.14. And the median was 0.31.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Zenlabs Ethica Cyclically Adjusted Revenue per Share Related Terms


Zenlabs Ethica Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Zenlabs Ethica's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zenlabs Ethica Cyclically Adjusted Revenue per Share Chart

Zenlabs Ethica Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 121.89 125.67 126.23 124.33 123.36

Zenlabs Ethica Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 124.33 124.57 125.34 124.86 123.36

BOM:530697 vs MCK, COR, CAH: Cyclically Adjusted Revenue per Share Comparison

For the Medical Distribution subindustry, Zenlabs Ethica's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zenlabs Ethica Cyclically Adjusted PS Ratio vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Zenlabs Ethica's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Zenlabs Ethica's Cyclically Adjusted PS Ratio falls into.


BOM:530697
61GF Score
Zenlabs Ethica Ltd BOM:530697
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zenlabs Ethica Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zenlabs Ethica's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=16.258/164.2724*164.2724
=16.258

Current CPI (Mar. 2026) = 164.2724.

Zenlabs Ethica Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 31.255 105.961 48.455
201609 34.459 105.961 53.422
201612 26.789 105.196 41.833
201703 31.407 105.196 49.045
201706 16.047 107.109 24.611
201709 33.716 109.021 50.803
201712 29.971 109.404 45.002
201803 29.944 109.786 44.805
201806 27.098 111.317 39.989
201809 23.379 115.142 33.355
201812 25.809 115.142 36.822
201903 29.106 118.202 40.450
201906 25.057 120.880 34.052
201909 23.482 123.175 31.317
201912 22.451 126.235 29.216
202003 23.444 124.705 30.882
202006 19.344 127.000 25.021
202009 23.100 130.118 29.163
202012 22.528 130.889 28.274
202103 14.179 131.771 17.676
202106 28.795 134.084 35.278
202109 28.506 135.847 34.471
202112 27.106 138.161 32.229
202203 22.410 138.822 26.518
202206 26.580 142.347 30.674
202209 27.088 144.661 30.760
202212 27.421 145.763 30.903
202303 22.629 146.865 25.311
202306 20.440 150.280 22.343
202309 22.349 151.492 24.234
202312 24.609 152.924 26.435
202403 24.001 153.035 25.763
202406 17.745 155.789 18.711
202409 20.658 157.882 21.494
202412 19.436 158.323 20.166
202503 20.042 157.552 20.897
202506 17.233 159.755 17.720
202509 19.839 162.289 20.081
202512 19.067 163.281 19.183
202603 16.258 164.272 16.258

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹123.36 mean?
Zenlabs Ethica (BOM:530697) has a Cyclically Adjusted Revenue per Share of ₹123.36 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zenlabs Ethica and its competitors.
Is Zenlabs Ethica's Cyclically Adjusted Revenue per Share too high?
Zenlabs Ethica's current Cyclically Adjusted Revenue per Share is ₹123.36. Overall, Zenlabs Ethica has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zenlabs Ethica's Cyclically Adjusted Revenue per Share compare to MCK and COR?
Zenlabs Ethica's Cyclically Adjusted Revenue per Share of ₹123.36 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Distribution company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Distribution industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zenlabs Ethica and its competitors. Zenlabs Ethica's current Cyclically Adjusted Revenue per Share is ₹123.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenlabs Ethica stock overvalued right now?
Based on GuruFocus' analysis, Zenlabs Ethica (BOM:530697) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹28.90, compared to a current price of ₹26.00 — trading 10% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹123.36. Zenlabs Ethica's overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Zenlabs Ethica (BOM:530697), the current Cyclically Adjusted Revenue per Share is ₹123.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zenlabs Ethica (BOM:530697) Overvalued in 2026?

Based on GuruFocus' analysis, Zenlabs Ethica stock appears to be undervalued. The current stock price of ₹26.00 is trading 10% below its estimated GF Value™ of ₹28.90. GuruFocus considers Zenlabs Ethica to be Modestly Undervalued.

Key valuation signals for BOM:530697:

  • Cyclically Adjusted Revenue per Share: ₹123.36
  • GF Value™: ₹28.90 vs. price of ₹26.00 (10% below fair value)
  • GF Score™: 61/100 with 3 warning signs

No single metric tells the full story. See the BOM:530697 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zenlabs Ethica Business Description

Address Plot No.194-195, 3rd Floor, Industrial Area, Phase-II, Ram Darbar, Chandigarh, IND, 160002
Zenlabs Ethica Ltd is a pharmaceutical company engaged in the trading of pharmaceutical formulations. It manufactures and markets drugs which include Gastrointestinal disorders, anti-diabetics, anti-hypertensive drugs, anti-infective, soaps, and anti-Bacterial drugs, nutraceuticals, and others. In addition, The company offers more than 600 products across therapeutic segments.
61GF Score

Get the complete analysis for BOM:530697

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹26.00
Price
₹28.90
GF Value